Screening for a family of targets rather than a single target is becoming more common in HTS, says Patrick Zarrinkar, Ph.D., director of molecular biology and technology development at Ambit Biosciences (www.ambitbio.com).
The firm offers a new technology to screen compounds against a large panel of kinases as opposed to the traditional approach of screening compounds against a single kinase in a single assay at a given time.
The KinomeScan platform screens small molecule compounds against a panel of 235 kinases simultaneously, providing a fast, accurate, uniform, and quantitative kinase profile for each compound, claims Dr. Zarrinkar
.KinomeScan turns the cross-reactivity issue of kinase inhibitors into a discovery advantage, revealing how well compounds bind not only to their intended targets, but also to mutations and unintended targets that may cause side effects or offer new uses for existing drugs, he
Our proprietary technology enables kinase researchers to efficiently perform a high-content and high-throughput screening assay under standardized conditions.We are currently working on expanding our technology to include more kinases in our assay panel, says Dr. Zarrinkar